Karyopharm Therapeutics Inc. (NASDAQ:KPTI) saw strong trading volume on Wednesday . 1,615,825 shares changed hands during mid-day trading, an increase of 318% from the previous session’s volume of 386,653 shares.The stock last traded at $9.83 and had previously closed at $9.73.

A number of research analysts recently commented on the stock. Vetr downgraded shares of Karyopharm Therapeutics from a “strong-buy” rating to a “buy” rating and set a $11.00 target price on the stock. in a research report on Wednesday. S&P Equity Research dropped their target price on shares of Karyopharm Therapeutics from $9.06 to $7.55 in a research report on Tuesday. Jefferies Group downgraded shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating and set a $14.00 target price on the stock. in a research report on Wednesday, June 1st. Raymond James Financial Inc. assumed coverage on shares of Karyopharm Therapeutics in a research report on Friday, May 27th. They issued an “outperform” rating and a $13.00 target price on the stock. Finally, Wedbush reaffirmed an “outperform” rating and issued a $14.00 target price on shares of Karyopharm Therapeutics in a research report on Friday, June 10th. Two research analysts have rated the stock with a sell rating and eleven have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $15.97.

The company’s 50 day moving average is $7.46 and its 200 day moving average is $7.99. The company’s market capitalization is $378.24 million.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings results on Thursday, August 4th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by $0.08. On average, equities analysts forecast that Karyopharm Therapeutics Inc. will post ($3.26) EPS for the current fiscal year.

In related news, major shareholder Ltd Chione sold 45,541 shares of the company’s stock in a transaction on Thursday, June 9th. The shares were sold at an average price of $9.21, for a total value of $419,432.61. Following the sale, the insider now directly owns 8,605,818 shares of the company’s stock, valued at $79,259,583.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.